“…Competitive inhibition of the glucuronidation processes between the two drugs is a possible explanation (19,20). Both Ezetimibe-associated myopathy drugs are glucuronidated by the uridine diphosphate glycosyltransferase 1 family, polypeptide A1 enzyme (21,22). The clinical relevance of inhibition of glucuronidation remains to be established and this possibility does not explain the appearance of muscle toxicity in the patient on ezetimibe alone.…”